Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
about
Thyroid lymphoma: recent advances in diagnosis and optimal management strategiesLoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.Tetraspanin CD37 protects against the development of B cell lymphomaC-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studiesDysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaClinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Genetic lesions in diffuse large B-cell lymphomasp63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrExpression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma.Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaStratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphomaA model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort StudyThe JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesisAberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas.Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatmentA clinician's guide to double hit lymphomas.Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone.
P2860
Q26827420-220C3541-0602-4B66-AA20-2E7207BBDE90Q27853399-EF76588B-72DA-4DB9-9CCA-44E31EE660F3Q33670880-6E51FFE1-BB26-48FB-B8E8-40F4536230C3Q33700531-4E53C979-058F-47AE-92F9-8FFB5D0B8160Q34000188-BD01B10A-597E-4D8D-872C-7B287ED9DB0CQ34509755-A0100B05-20D4-4CF4-840A-1A52139A1C79Q35150618-3254779F-922E-4D66-A32B-5CD1D48C8029Q35742364-28634CB8-BD75-429B-A759-019BECA79295Q35742367-C9D0D36A-9401-405D-A7ED-073215BCF5A0Q35755485-58F21710-77B7-4C67-A7F8-2B3D91511EF6Q35974341-2139E90A-7744-44EF-846F-F4562D18CBD0Q36681461-4BD0ADD9-F35B-4B80-AF6D-54A1FC174D01Q36876967-26A685AE-4967-4A0A-9BB6-5A3AC9ECF65DQ37006876-D9607A6E-CAB2-4756-B891-8165113404AEQ37020239-8E44E49F-8FD0-49BB-BF15-76581B1A0E3FQ37100081-CA63699A-23C3-49C8-9248-3092AED69760Q37109671-15AEF421-7122-450A-8550-1792769B33D8Q37437423-EBD74C4E-6439-4059-A794-08A63E201069Q37589239-E5CD69B7-5E14-435F-AFF4-42177A76A29FQ37621025-521C95D1-7300-478E-BB9D-4E712C697755Q37624237-99F8274A-2ACA-46D9-B8C8-BCF98256A16AQ37706132-7804B9D1-25D8-4988-82E3-1FDEA2FA3DD5Q37708916-5693672F-5868-48B7-AD7C-BFCFCDA63E28Q38244519-83C0F4DA-C9B0-4B83-8795-7F0FB4F9198FQ38296091-45D45A38-AE42-43F8-B992-01D1A08E24F0Q38376595-EF36E5EB-B2A3-4ABA-BA30-F3D0090BB997Q38398064-3BCB80C1-BDD0-4807-BF9D-6DCBD0979022Q38563530-4D7DB9BD-662C-4FCC-98A6-ABEC0967F36EQ38636154-C5936EA6-52E8-43FA-9A51-56526A881984Q38656983-D8333C06-33D9-4309-A550-618FDD56B960Q38882112-F4C9DD27-F1A3-49FE-853F-B100AD46D664Q38975357-A775C788-45BB-4DE6-8409-E98ADBFCD282Q39406673-421784DB-B9F5-47C8-B981-9A8A5E2389AFQ39669214-9213020E-77DE-4976-B207-40C75857D271Q40154948-3EA14EBC-6118-4C1D-8957-EC09048EECE9Q40477997-B7423BB2-A069-45CD-A555-D08B7F2B8BBEQ41507351-4FA805A8-AEF9-4C5E-B4B5-EFDAA1C6253FQ42230312-521F4D9C-5D6E-408A-8EB2-DC13C748D087Q43764468-D945FC55-ED03-4986-8ADB-E0AEE66FF650Q44080067-B995098A-06C9-4CCD-A4A7-1326EEC985A4
P2860
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@ast
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@en
type
label
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@ast
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@en
prefLabel
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@ast
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@en
P2093
P2860
P50
P1433
P1476
Patients with diffuse large B- ...... CHOP Consortium Program Study.
@en
P2093
Alexander Tzankov
Andres J M Ferreri
April Chiu
Attilio Orazi
Brad S Kahl
Carlo Visco
Cherie H Dunphy
Emanuele S G d'Amore
Eric D His
Huan-You Wang
P2860
P304
P356
10.3324/HAEMATOL.2012.066209
P50
P577
2012-08-28T00:00:00Z